LONDON — A major advancement in the treatment of pulmonary arterial hypertension (PAH) was detailed on August 8, 2026, as The Lancet published the results of the phase 3 ADVANCE OUTCOMES study, demonstrating that the oral, once-daily drug ralinepag significantly reduces the risk of clinical worsening in patients with the rare and progressive cardiovascular disease www.thelancet.com .

PAH is a severe condition characterized by high blood pressure in the arteries of the lungs, which progressively strains the right side of the heart and can lead to heart failure link.springer.com . Ralinepag is a next-generation, selective prostacyclin IP receptor agonist developed specifically to treat PAH by dilating pulmonary blood vessels and inhibiting cell proliferation www.thelancet.com . The ADVANCE OUTCOMES trial—a randomized, double-blind, placebo-controlled phase 3 study led by Vallerie V. McLaughlin and colleagues—evaluated the long-term efficacy and safety of adding once-daily oral ralinepag to standard background PAH therapies connect.uclahealth.org .

A 55% Reduction in Clinical Worsening

The primary results of the trial were striking. According to data released by United Therapeutics, ralinepag reduced the risk of a first clinical worsening event by 55% compared with placebo www.drugs.com . The hazard ratio stood at 0.45 (95% CI [0.33–0.62]; p<0.0001), signaling a robust and highly statistically significant benefit for patients receiving the investigational drug www.drugs.com .

In a companion commentary published in the same issue of The Lancet, Dr. Stephen C. Mathai described the findings as a vital "step forward" in pulmonary arterial hypertension management, noting that an effective, once-daily oral prostacyclin pathway agent could dramatically simplify treatment regimens for patients currently burdened by continuous intravenous or inhaled therapies www.thelancet.com .

The Path to FDA Approval

The publication of the ADVANCE OUTCOMES data follows closely on the heels of regulatory action. United Therapeutics announced that it submitted a New Drug Application (NDA) for ralinepag to the U.S. Food and Drug Administration in June 2026 ir.unither.com . If approved, ralinepag would become a critical oral option in a therapeutic area where many of the most potent prostacyclin therapies require cumbersome continuous intravenous infusions or multiple daily inhalations.

Shifting the Treatment Paradigm

For the medical community, the success of the ADVANCE OUTCOMES trial represents a potential paradigm shift. By offering a highly effective oral alternative that targets the prostacyclin pathway—the same pathway targeted by life-saving but difficult-to-administer intravenous epoprostenol—ralinepag could vastly improve the quality of life for thousands of PAH patients globally www.ecrjournal.com . As the FDA reviews the June 2026 NDA, clinicians and patients alike are watching closely to see if this next-generation IP receptor agonist will become a new cornerstone of multidrug PAH therapy in 2027. Follow the latest cardiovascular research via The Lancet and the American College of Cardiology.

Related Topics:

#FDA#Clinical Trials#medical research#The Lancet#Pulmonary Arterial Hypertension#Ralinepag#Cardiovascular Disease
olivia
oliviaStaff Writer

Related Articles

Comments (0)

No comments yet. Be the first to share your thoughts!